Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-22
2005-03-22
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S002600, C530S300000, C530S350000, C435S007100
Reexamination Certificate
active
06869931
ABSTRACT:
Peptide analogs the high molecular weight kininogen domain 3 are potent inhibitors of angiogenesis. The peptides have the formula (a) X1-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-X2, (b) X3-Cys-Val-Gly-Cys-X4, (c) X5-Leu-Asp-X7-Asn-Ala-Glu-Val-Tyr-X6, or (d) Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-X7-Ser-Lys-Glu-Serwherein:X1, X2, X3, X4, X5, and X6are from zero to twelve amino acids, independently the same or different, more preferably from zero to six amino acids, and;X7is Ala or Cys.The peptides may also comprise biologically active fragments of high molecular weight kininogen domain 3. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.
REFERENCES:
patent: 5596079 (1997-01-01), Smith et al.
patent: 5756291 (1998-05-01), Griffin et al.
patent: 5786365 (1998-07-01), Heitsch et al.
patent: 5817748 (1998-10-01), Miller et al.
patent: 5830671 (1998-11-01), Dennis et al.
patent: 5846821 (1998-12-01), Guerinot et al.
patent: 6143719 (2000-11-01), Schmaier et al.
patent: 7082172 (1995-03-01), None
patent: 8208692 (1996-08-01), None
patent: WO 9641640 (1996-12-01), None
R.W. Colman, et al., Abstract #701, “Inhibition Of Angkiogenesis By Peptides Derived From Kininogen”,Bloodvol. 92, No. 10 Supplement 1, Nov. 15, 1998.
Robert W. Colman et al., “Contact System: A Vascular Biology Modulator With Anticoagulant Profibrinolytic, Antiadhesive, and Proinflammatory Attributes”,Blood, vol. 90, No. 10 pp. 3819-3843 (Nov. 15, 1997).
Robert W. Colman, et al., “Binding of High Molecular Weight Kininogen to Human Endothelial Cells Is Mediated via a Site within domains 2 and 3 of the Urokinase Receptor”,J. Clin. Invest., vol. 100, No. 6, pp. 1481-1487 (Sep. 1997).
Mohammad M.H. Khan et al., “Three noncintiguous peptides comprise binding sites on high-molecular-weight kininogen to neutrophils”,The American Physiological Society (Heart Circ. Physiol. 44): H145-150, vol. 275 (1998).
Yanina T. Wachtfogel et al., “High Molecular Weight Kininogen Binds to Mac-1 on Neutrophils by Its Heavy Chain (Domain 3) and Its Light Chain (Domain 5)”,The Journal of Biological Chemistry, vol. 269, No. 30, pp. 19307-19312 (Jul. 29, 1994).
Shinji Asakura et al., “Inhibition of Cell Adhesion by High Molecular Weight Kininogen”,The Journal of Cell Biology, vol. 116, No. 2, pp. 465-476 (Jan. 1992).
Colman et al., Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and proinflammatory Attributes. Blood, Nov. 15, 1997. vol. 90, No. 10, pp. 3819-3843.
Lottspeich et al., “The Amino Acid Sequence of the Light Chain of Human High-Molecular-Mass Kininogen”,European Jounal of Biochemistry, 1985, vol. 152, pp. 307-314.
Takagaki et al., “Cloning and Sequence Analysis of cDNAs for Human High Molecular Weight and Low Molecular Weight Prekininogens”,The Journal of Biological Chemistry, Jul. 15, 1985, vol. 260, No. 14, pp. 8601-8609.
Kitamura et al., “Structural Organization of Human Kininogen Gene and a Model for its Evolution”,The Journal of Biological Chemistry, Jul. 15, 1985, vol. 260, No. 15, pp. 8610-8617.
Auerswald et al., “Cloning, expression, and characterization of human kininogen demain 3”, FEBS Letters, vol. 321, No. 1, pp. 93-97, 1993.
Satya P. Kunapuli et al., “Deletion Mutagenesis of High Molecular Weight Kininogen Light Chain”,The Journal of Biological Chemistryvol. 268, No. 4, pp. 2486-2492 (Feb. 5, 1993).
Drinker Biddle & Reath LLP
Low Christopher S. F.
Robinson Hope A.
Temple University - Of The Commonwealth System of Higher Educati
LandOfFree
Inhibition of angiogenesis by high molecular weight... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of angiogenesis by high molecular weight..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of angiogenesis by high molecular weight... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3447512